Tenderwize
Wróć do wyszukiwania

Conclusion of non-exclusive drug discount agreement according to §130a(8) SGB V via Open-House model for the active substance Trientin (ATC: A16AX12)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 34 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Trientin (ATC-Code nach WHO: A16AX12)

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

30 / 100

Czynniki ryzyka

No minimum volume guaranteed; actual prescriptions depend on doctors and pharmacies. Revenue may be negligible.

AOK PLUS may terminate the Open-House procedure if exclusive agreements are concluded, typically 8-12 months after publ...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Non-exclusive drug discount agreements for the active substance Trientin (ATC: A16AX12)
  • Open-House model allowing any eligible pharmaceutical entrepreneur to participate
Pokaż pełne podsumowanie

This tender is a non-exclusive drug discount agreement (Open-House model) for the active substance Trientin (ATC: A16AX12) organized by AOK PLUS. It is not a traditional public procurement but is published for transparency. Any eligible pharmaceutical entrepreneur can participate at any time until 30 September 2026, subject to rolling submission deadlines. No minimum purchase volumes are guaranteed, and the agreement may be terminated early if exclusive agreements are concluded.

Ryzyka

No minimum volume guaranteed; actual prescriptions depend on doctors and pharmacies. Revenue may be negligible.

AOK PLUS may terminate the Open-House procedure if exclusive agreements are concluded, typically 8-12 months after publ...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG

Eligibility

  • Must submit self-declaration on absence of exclusion grounds ($$§123,124 GWB)

Administrative

  • Must submit declaration on compliance with EU Russia sanctions (Regulation 833/2014)

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No specific award criteria disclosed; participation is based on acceptance of the framework terms.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Conclusion of non-exclusive drug discount agreement according to §130a(8) SGB V via Open-House model for the active substance Trientin (ATC: A16AX12)

Non-exclusive framework agreement for drug discounts on Trientin. Participation open to all eligible pharmaceutical companies. No minimum volumes. Agreement ends 30 September 2026.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Sep 2025 - Sep 2026

Kategoria

Pharmaceutical products

Kryteria udzielenia

No specific award criteria disclosed; participation is based on acceptance of the framework terms.

Termin

Deadline Sep 30, 2026

Szczegóły zamówienia

Data publikacji
31 Jul 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
506508-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3